Cepheid's Q4 Revenues Rise 30 Percent

The firm's instrument and reagents growth were strong for the fourth quarter, as the firm beat analysts' estimates.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories